Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 08-Jan-24 6:14 PM View:  | Astle Christopher SVP & Chief Financial Officer | Zymeworks Inc. (ZYME) | 08-Jan-24 | Option Sale | 1,431 | $11.22 | $16,049.50 | (18%) 7.93K to 6.5K | |
| 08-Jan-24 6:23 PM View: | Galbraith Kenneth Chair & CEO Director | Zymeworks Inc. (ZYME) | 08-Jan-24 | Option Sale | 5,706 | $11.22 | $63,996.20 | (19%) 29.47K to 23.76K | |
| 08-Jan-24 6:01 PM View: | Moore Paul Andrew Chief Scientific Officer | Zymeworks Inc. (ZYME) | 08-Jan-24 | Option Sale | 2,339 | $11.22 | $26,233.30 | (24%) 9.71K to 7.37K | |
| 08-Jan-24 6:14 PM View: | Astle Christopher SVP & Chief Financial Officer | Zymeworks Inc. (ZYME) | 05-Jan-24 | Option Exercise | 10,500 | -- | -- | 526% 2.0K to 12.5K | |
| 08-Jan-24 6:23 PM View: | Galbraith Kenneth Chair & CEO Director | Zymeworks Inc. (ZYME) | 05-Jan-24 | Option Exercise | 47,666 | -- | -- | 100% 0 to 47.67K | |
| 08-Jan-24 6:01 PM View: | Moore Paul Andrew Chief Scientific Officer | Zymeworks Inc. (ZYME) | 05-Jan-24 | Option Exercise | 17,166 | -- | -- | 100% 0 to 17.17K | |
| 08-Jan-24 6:14 PM View: | Astle Christopher SVP & Chief Financial Officer | Zymeworks Inc. (ZYME) | 05-Jan-24 | Option Sale | 4,563 | $10.65 | $48,606.00 | (37%) 12.5K to 7.93K | |
| 08-Jan-24 6:23 PM View: | Galbraith Kenneth Chair & CEO Director | Zymeworks Inc. (ZYME) | 05-Jan-24 | Option Sale | 18,198 | $10.65 | $193,849.00 | (38%) 47.67K to 29.47K | |
| 08-Jan-24 6:01 PM View: | Moore Paul Andrew Chief Scientific Officer | Zymeworks Inc. (ZYME) | 05-Jan-24 | Option Sale | 7,460 | $10.65 | $79,465.40 | (43%) 17.17K to 9.71K | |
| 11-Dec-23 8:00 PM View: | Astle Christopher SVP & Chief Financial Officer | Zymeworks Inc. (ZYME) | 11-Dec-23 | Option Sale | 886 | $9.13 | $8,089.27 | (31%) 2.88K to 2.0K | |
| 11-Dec-23 8:00 PM View: | Astle Christopher SVP & Chief Financial Officer | Zymeworks Inc. (ZYME) | 11-Dec-23 | Option Exercise | 1,550 | -- | -- | 116% 1.33K to 2.88K | |
| 21-Jun-23 4:04 PM View: | Ecor1 Capital, LLC 10% Owner | Zymeworks Inc. (ZYME) | 16-Jun-23 | Market Purchase | 3,350,000 | $8.12 | $27,202,000.00 | 33% 10.09M to 13.44M | (5%) |
| 30-Mar-23 5:47 PM View: | Ecor1 Capital, LLC 10% Owner | Zymeworks Inc. (ZYME) | 28-Mar-23 | Market Purchase | 200,000 | $8.00 | $1,600,000.00 | 2% 9.89M to 10.09M | (4%) |
| 14-Mar-23 5:00 PM View: | Klompas Neil A President & COO | Zymeworks Inc. (ZYME) | 10-Mar-23 | Option Sale | 2,977 | $7.83 | $23,297.70 | (14%) 20.71K to 17.73K | |
| 14-Mar-23 5:00 PM View: | Klompas Neil A President & COO | Zymeworks Inc. (ZYME) | 10-Mar-23 | Option Exercise | 5,208 | -- | -- | 34% 15.5K to 20.71K | |
| 23-Jan-23 6:00 PM View: | Ecor1 Capital, LLC 10% Owner | Zymeworks Inc. (ZYME) | 20-Jan-23 | Purchase | 163,400 | $9.88 | $1,615,090.00 | 2% 9.72M to 9.89M | |
| 23-Jan-23 6:00 PM View: | Ecor1 Capital, LLC 10% Owner | Zymeworks Inc. (ZYME) | 19-Jan-23 | Purchase | 144,100 | $9.49 | $1,367,640.00 | 2% 9.58M to 9.72M | |
| 18-Jan-23 6:27 PM View: | Ecor1 Capital, LLC 10% Owner | Zymeworks Inc. (ZYME) | 18-Jan-23 | Purchase | 203,000 | $10.00 | $2,029,050.00 | 2% 9.38M to 9.58M | |
| 18-Jan-23 6:27 PM View: | Ecor1 Capital, LLC 10% Owner | Zymeworks Inc. (ZYME) | 17-Jan-23 | Purchase | 440,000 | $9.80 | $4,313,850.00 | 5% 8.94M to 9.38M | |
| 18-Jan-23 6:27 PM View: | Ecor1 Capital, LLC 10% Owner | Zymeworks Inc. (ZYME) | 13-Jan-23 | Purchase | 342,100 | $9.81 | $3,354,630.00 | 4% 8.59M to 8.94M | |
| 12-Jan-23 4:47 PM View: | Ecor1 Capital, LLC 10% Owner | Zymeworks Inc. (ZYME) | 11-Jan-23 | Market Purchase | 106,300 | $7.87 | $836,910.00 | 1% 8.49M to 8.59M | (2%) |
| 12-Jan-23 4:47 PM View: | Ecor1 Capital, LLC 10% Owner | Zymeworks Inc. (ZYME) | 10-Jan-23 | Market Purchase | 920,000 | $7.65 | $7,037,170.00 | 12% 7.57M to 8.49M | < 1% |
| 14-Dec-22 8:00 PM View: | Astle Christopher SVP & Chief Financial Officer | Zymeworks Inc. (ZYME) | 12-Dec-22 | Option Exercise | 1,550 | -- | -- | 231% 0.67K to 2.22K | |
| 14-Dec-22 8:00 PM View: | Astle Christopher SVP & Chief Financial Officer | Zymeworks Inc. (ZYME) | 12-Dec-22 | Planned Option Sale | 887 | $6.01 | $5,330.87 | (40%) 2.22K to 1.33K | |
| 14-Nov-22 9:41 PM View: | Josephson Neil Chief Medical Officer | Zymeworks Inc. (ZYME) | 10-Nov-22 | Option Exercise | 5,885 | -- | -- | 53% 11.04K to 16.92K | |
| 14-Nov-22 9:41 PM View: | Josephson Neil Chief Medical Officer | Zymeworks Inc. (ZYME) | 10-Nov-22 | Market Option Sale (Planned) | 2,475 | $8.10 | $20,045.00 | (15%) 16.92K to 14.45K | |
| 17-Oct-22 9:48 PM View: | Redmile Group, LLC 10% Owner | Zymeworks Inc. (ZYME) | 13-Oct-22 | Grant | 30,481 | $5.03 | $153,435.00 | < 1% 6.05M to 6.08M |
